v3.26.1
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment - Footnotes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income [1] $ 3,170 $ 2,785
Restructuring charges   666
Biopharma [Member]    
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income 6,838 7,069
Biopharma [Member] | ViiV [Member]    
Segment Reporting Information [Line Items]    
Dividend income (82) (39)
Other Business Activities [Member]    
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income [1],[2] $ (1,668) (1,384)
Other Business Activities [Member] | Reclassification Other [Member]    
Segment Reporting Information [Line Items]    
Income from continuing operations before provision/(benefit) for taxes on income   $ 36
[1] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $36 million in the first quarter of 2025 from Other business activities to Biopharma to conform to the current period presentation.
[2] Other business activities include revenues and costs associated with PC1 and our former operating segment, Pfizer Ignite, as well as costs that we do not allocate to our operating segments, per above.